Kemp Dolliver
Stock Analyst at Brookline Capital
(0.49)
# 4,138
Out of 5,044 analysts
16
Total ratings
33.33%
Success rate
-18.04%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.55 | - | 1 | Aug 19, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $5.01 | +259.28% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.66 | +1,103.01% | 1 | Jul 15, 2025 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $3.61 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $1.54 | +133.77% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.02 | +1,682.18% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.28 | +2,353.13% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $55.88 | +78.95% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.07 | +2,653.62% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $7.70 | +224.68% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.04 | +272.02% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.69 | +1,064.65% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.75 | +656.56% | 1 | Feb 2, 2022 |
Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.55
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $5.01
Upside: +259.28%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.66
Upside: +1,103.01%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.61
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $1.54
Upside: +133.77%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.02
Upside: +1,682.18%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.28
Upside: +2,353.13%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $55.88
Upside: +78.95%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.07
Upside: +2,653.62%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $7.70
Upside: +224.68%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $5.04
Upside: +272.02%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.69
Upside: +1,064.65%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.75
Upside: +656.56%